The effects of Yishen Qutong granula on pain sensitization and bone destruction of rats with bone cancer pain

Objective:To study the effects of Yishen Qutong granula on pain sensitization and bone destruction of rats with bone cancer pain.Methods:Walker256 cells were passaged in ascites and injected into the tibia of female Wistar rats to prepare the bone cancer pain model.On the 14th day after model establishment,60 rats were randomly divided into model group,sham-operated group,Yishen Qutong granula low,middle,high dose group and tramadol hydrochloride positive control group.After continuous administration for 14 days,the mechanical pain threshold,thermal threshold and weight-bearing difference of both hind limbs were observed.Results:Compared with the model group,Yishen Qutong groups increased the mechanical pain threshold,thermal pain threshold and reduced the weight difference of both hind limbs(P<0.05).Compared with the positive drug group,there was no significant difference in increasing the mechanical pain threshold and thermal pain threshold of rats in the medium dose group of Yishen Qutong(P>0.05),and Yishen Qutong granula significantly reduced the weight-bearing difference of hind limbs in all groups(P<0.05).Conclusion:Yishen Qutong granula can relieve pain sensitization and alleviate bone damage in rats with bone cancer pain.

Influence of Yishen Guben Qutong decoction combined with menatetrenone soft capsule on bone metabolism,bone conversion index and clinical efficacy in osteoporosis patients

Objective:To observe the effect of tetradecylene naphthalene soft capsule combined with Yishen Gubenyutong Decoction on bone metabolism and bone turnover in patients with osteoporosis and its clinical efficacy.Methods:A total of 100 patients with primary osteoporosis(all were treated by our hospital from February 2017 to June 2018)were divided into two groups.The control group(50 cases)was given to menatetrenone capsules.Treatment,observation group(50 cases)combined with Yishen Gubenqiaotongtong on the basis of the treatment of the control group,6 months for a course of treatment.The bone metabolic markers,bone mineral density changes and clinical efficacy were measured before and after treatment.Results:The total effective rate of the observation group was higher than that of the control group.After treatment,the observation group showed serum calcium(Ca),serum alkaline phosphatase(ALP)and typeⅠcollagen.The level of cross-linked C-terminal peptide(CTX-1)was lower than that of the control group.After treatment,the osteocalcin(OC)in the observation group was higher than that in the control group,and the bone mineral density(BMD)of lumbar vertebrae L2-4,femoral neck and femur trochanter in the observation group were higher than those in the control group.Conclusion:Menatetrenone soft capsule combined with Yishen Gubenyutong Decoction has good clinical effect on osteoporosis patients and it is worth further promotion in clinic.

Network Pharmacology-based Analysis on Determining the Mechanisms of Yishen Qutong Granules(益肾祛痛颗粒)in Alleviating Cancer-related Fatigue

Cancer-related fatigue(CRF)is associated with cancer-related anemia(CRA).As the common comorbidities of cancer,both of them can seriously affect the quality of patient life.Yishen Qutong Granules(益肾祛痛颗粒,YSQTG)have achieved good curative effects in the treatment of CRA.However,the mechanism of whether it can alleviate CRF needs further confirmation.We used network pharmacology and molecular docking to investigate the molecular mechanism and the effective compounds of the prescription.Through the analysis and research in this paper,we obtained 76 effective compounds and 76 drug-disease intersection targets to construct a network,indicating that quercetin,luteolin,baicalein,β-sitosterol and stigmasterol were possibly the most important compounds in YSQTG.The key targets of YSQTG for CRF were mainly enriched in IL-17 and TNF pathways.816 GO entries and 113 pathways were obtained by GO and KEGG enrichment,respectively,which proved that YSQTG might have a comprehensive therapeutic effect on CRF mainly through regulating IL-17,TNF,MAPK,NF-κB and chemokines,as well as cholinergic synapse and 5-HT synapse pathways.The results of molecular docking showed thatβ-sitosterol and stigmasterol could form PI-Alkyl or Alkyl hydrophobic interactions with CXCL8 and ESR1 at residues LEU25,ARG26,PHE65,ALA69 and LEU346,ALA350,LEU391,PHE404,LEU525,VAL533,respectively.In conclusion,the therapeutic effect of YSQTG on CRF is based on the comprehensive pharmacological effect of multicomponent,multitarget,and multichannel pathways.This study provides a theoretical basis for further experimental research.

Clinical Study on Treatment to Ankylosing Spondylitis with Fengshi Qutong Capsule-Diclofenac Sodium Combination

Objective:To discuss the clinical study on Fengshi Qutong capsules combined with diclofenac sodium in the treatment of ankylosing spondylitis.Methods:80 patients who were treated for ankylosing spondylitis from June 2019 to June 2020 were selected and divided into two groups.The experimental group was treated with Fengshi Qutong capsules combined with diclofenac sodium,and the control group was treated with sulfasalazine enteric-coated tablets.Results:The treatment efficacy,VAS score,BASDAI score,BASFI score,CRP level,TNF-α level,IL-Iβ level,and the incidence of adverse reactions between the two groups were significantly different(P<0.05).Conclusion:The application of Fengshi Qutong capsules combined with diclofenac sodium in the treatment of patients with ankylosing spondylitis is beneficial to improve the treatment efficacy,reduce the levels of CRP,TNF-α,and IL-Iβ,reduce the incidence of adverse reactions,and reduce the VAS,BASDAI and BASFI scores,rendering it of important clinical value.

Network Pharmacology and in vitro Experimental Veriflcation on Intervention of Quercetin, Present in Chinese Medicine Yishen Qutong Granules, on Esophageal Cancer

Objective: To explore the potential mechanism of Yishen Qutong Granules(YSQTG) for the treatment of esophageal cancer using network pharmacology and experimental research. Methods: The effective components and molecular mechanism of YSQTG in treating esophageal cancer were expounded based on network pharmacology and molecular docking. The key compound was identified by high-performance liquid chromatography and mass spectrometry(HPLC-MS) to verify the malignant phenotype of the key compounds in the treatment of esophageal cancer. Then, the interaction proteins of key compounds were screened by pull-down assay combined with mass spectrometry. RNA-seq was used to screen the differential genes in the treatment of esophageal cancer by key compounds, and the potential mechanism of key compounds on the main therapeutic targets was verified. Results: Totally 76 effective compounds of YSQTG were found, as well as 309 related targets, and 102 drug and disease interaction targets. The drug-compound-target network of YSQTG was constructed, suggesting that quercetin, luteolin, wogonin, kaempferol and baicalein may be the most important compounds, while quercetin had higher degree value and degree centrality, which might be the key compound in YSQTG. The HPLC-MS results also showed the stable presence of quercetin in YSQTG. By establishing a protein interaction network, the main therapeutic targets of YSQTG in treating esophageal cancer were Jun proto-oncogene, interleukin-6, tumor necrosis factor, and RELA proto-oncogene. The results of cell function experiments in vitro showed that quercetin could inhibit proliferation, invasion, and clonal formation of esophageal carcinoma cells. Quercetin mainly affected the biological processes of esophageal cancer cells, such as proliferation, cell cycle, and cell metastasis. A total of 357 quercetin interacting proteins were screened, and 531 genes were significantly changed. Further pathway enrichment analysis showed that quercetin mainly affects the metabolic pathway, MAPK signaling pathway, and nuclear factor kappa B(NF-κB) signaling pathway, etc. Quercetin, the key compound of YSQTG, had stronger binding activity by molecular docking. Pull-down assay confirmed that NF-κB was a quercetin-specific interaction protein, and quercetin could significantly reduce the protein level of NF-κB, the main therapeutic target. Conclusion: YSQTG can be multi-component, multi-target, multi-channel treatment of esophageal cancer, it is a potential drug for the treatment of esophageal cancer.

通络祛痛膏循经取穴贴敷对腰间盘突出患者止痛效果的随机对照研究

目的通过随机对照研究通络祛痛膏循经取穴贴敷对腰间盘突出患者止痛效果。方法110例腰间盘突出患者,采用随机数字表法分为观察组和对照组,每组55例。观察组采用循经取穴贴敷通络祛痛膏,对照组采用常规阿是穴贴敷通络祛痛膏。比较两组患者治疗前后及随访期间视觉模拟评分法(VAS)评分、伴随症状缓解效果、安全性。结果治疗前,观察组患者VAS评分(5.98±1.84)分与对照组的(6.10±2.20)分比较,无明显差异(P>0.05)。治疗后,两组患者VAS评分均低于治疗前,且观察组患者VAS评分(2.93±1.30)分低于对照组的(3.97±2.29)分(P<0.05)。观察组治疗后2周、1个月、3个月随访VAS评分分别为(2.79±1.68)、(2.67±1.38)、(2.37±1.95)分,均低于治疗前(P<0.05),略低于治疗后,但无明显差异(P>0.05)。对照组患者治疗后2周、1个月、3个月随访VAS评分分别为(3.67±2.54)、(4.67±2.63)、(4.59±2.98)分,治疗后2周随访VAS评分略低于治疗后,治疗后1、3个月随访VAS评分均高于治疗后,但均无明显差异(P>0.05)。观察组治疗后2周、1个月、3个月随访VAS评分均低于对照组(P<0.05)。观察组患者伴随症状缓解显效率94.6%高于对照组的76.4%(P<0.05)。观察组与对照组患者伴随症状缓解总有效率均为98.2%,无明显差异(P>0.05)。治疗过程中两组各发生轻度皮肤瘙痒3例,局部涂抹药膏后缓解,局部皮肤后期有轻微结痂,无感染及瘢痕产生。两组均未发生严重安全性问题,两组安全性比较无明显差异(P>0.05)。结论通络祛痛膏循经取穴贴敷疗法对腰间盘突出患者止痛效果及远期疗效优于常规阿是穴贴敷,且在改善伴随症状上循经取穴贴敷显效率高于阿是穴贴敷。

腕踝针结合乌芍祛痛散治疗肾绞痛临床研究

目的:观察腕踝针结合乌芍祛痛散治疗肾绞痛的疗效。方法:60例随机分为观察组和对照组各30例,观察组用腕踝针及乌芍祛痛散,对照组给予帕瑞昔布钠治疗。结果:观察组治疗后0.5、1、24h的VAS评分,对照组治疗后1、24h的VAS评分均降低(P<0.05)。观察组的疼痛缓解时间短于对照组(P<0.05),不良反应发生率低于对照组(P<0.05)。结论:腕踝针及乌芍祛痛散治疗肾绞痛能够快速缓解肾绞痛,不良反应少。

通络祛痛膏联合塞来昔布治疗风湿瘀阻证膝骨关节炎的效果

目的:探讨通络祛痛膏联合塞来昔布治疗风湿瘀阻证膝骨关节炎(knee osteoarthritis,KOA)的效果。方法:选取2021年1—12月徐州市中心医院骨科收治的130例风湿瘀阻证KOA患者。根据简单信封随机法将其分为对照组和观察组,各65例。对照组给予塞来昔布胶囊,观察组在对照组基础上给予通络祛痛膏。比较两组治疗前后症状评分、临床疗效及不良反应。结果:治疗后,两组KOA严重性指数(index of severity of osteoarthritis,ISOA)评分低于治疗前,观察组低于对照组,差异有统计学意义(P<0.05)。治疗后,观察组临床疗效优于对照组,总有效率高于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率略低于对照组,但差异无统计学意义(P>0.05),观察组未出现与中药外敷相关的局部皮肤过敏反应。结论:通络祛痛膏联合塞来昔布治疗KOA,能够缓解症状,且不增加药物相关的不良反应,用药安全性良好。

通络祛痛膏治疗肩周炎的临床疗效观察

目的探讨通络祛痛膏治疗肩周炎的临床疗效。方法98例肩周炎患者,随机分为对照组和观察组,每组49例。对照组使用常规治疗,观察组在对照组基础上使用通络祛痛膏治疗。比较两组临床疗效,肩关节功能评分,血清炎性因子[C反应蛋白(CRP)、白细胞介素-6(IL-6)、白细胞介素-10(IL-10)、肿瘤坏死因子-α(TNF-α)、基质金属蛋白酶-9(MMP-9)]水平,世界卫生组织生活质量评估简表(WHOQOL-BREF)评分。结果观察组治疗总有效率为95.92%,明显高于对照组的73.47%,差异具有统计学意义(P<0.05)。治疗后,观察组患者的疼痛、肌力、日常生活能力、肩关节活动度评分分别为(13.27±1.64)、(23.46±2.21)、(17.62±1.79)、(36.48±3.72)分,均明显高于对照组的(9.89±1.52)、(20.17±2.36)、(14.01±1.56)、(27.69±4.03)分,差异具有统计学意义(P<0.05)。治疗后,观察组患者的CRP(2.30±0.64)mg/L、IL-6(43.07±12.56)ng/L、TNF-α(15.89±2.97)ng/L、MMP-9(23.38±3.94)ng/ml均低于对照组的(5.95±1.26)mg/L、(62.54±17.07)ng/L、(22.74±3.48)ng/L、(36.17±4.49)ng/ml,IL-10(38.45±5.28)ng/L高于对照组的(25.64±4.67)ng/L,差异具有统计学意义(P<0.05)。治疗后,观察组患者的生理领域、社会关系领域、环境领域、心理领域评分分别为(18.06±2.13)、(16.27±1.56)、(17.74±2.15)、(18.01±2.12)分,均高于对照组的(14.35±2.01)、(13.09±1.41)、(15.14±1.90)、(14.27±1.96)分,差异具有统计学意义(P<0.05)。结论通络祛痛膏治疗肩周炎的临床疗效显著,能有效抑制肩周炎症反应,缓解肩周疼痛,改善肩功能及活动度。

益肾祛痛颗粒抑制乳腺癌骨转移及对骨桥蛋白表达的影响

目的验证益肾祛痛颗粒(Yishen Qutong Granule,YSQTKL)对小鼠乳腺癌骨转移的抑制效果并探讨其作用机制。方法随机将5周龄BABL/c小鼠分为空白组、假手术组、模型组、YSQTKL高中低剂量组,每组8只,胫骨种植4T1.2细胞制备乳腺癌骨转移模型后,分别给予蒸馏水或相应浓度YSQTKL溶液灌胃,4周后处死取材,用Micro-CT分析松质骨骨含量/组织含量[bone volume/tissue volume(BV/TV)]、松质骨厚度[trabecular bone thickness(Tb.Th)]、松质骨数目[trabecular bone number(Tb.N)]以及松质骨间隙[trabecular bone separation(Tb.Sp)]等骨质破坏情况,测量骨转移瘤瘤重,HE染色进行组织学诊断,免疫组化法检测骨桥蛋白(Osteopontin,OPN)的表达情况。结果除空白组及假手术组外,造模各组均成瘤,组织学诊断显示乳腺癌骨转移。相对于模型组,YSQTKL低剂量组瘤重更小,差异具有统计学意义(P<0.05);Micro-CT结果显示,相对于空白组及假手术组,模型组松质骨除Tb.N无差异外,BV/TV、Tb.Th以及Tb.Sp均升高(P<0.05),而YSQTKL组松质BV/TV、Tb.Th以及Tb.Sp较模型组降低(P<0.05),骨破坏程度更低;免疫组化结果显示,相对于空白组及假手术组,模型组OPN表达升高,而YSQTKL各组OPN表达较模型组低,其中低剂量组差异具有统计学意义(P<0.05)。结论益肾祛痛颗粒可抑制小鼠乳腺癌骨转移,且下调骨桥蛋白表达是其可能作用机制。

急性外侧踝关节扭伤“马镫”式固定配合通络祛痛膏的疗效

目的观察通络祛痛膏结合医用橡皮膏胶带“马镫”式固定治疗急性外侧踝关节扭伤(LAS)的效果。方法回顾性分析2017年1月至2021年8月漯河市中医院门诊收治的符合纳入标准的85例急性LAS患者,其中42例患者接受通络祛痛膏治疗(通络膏组),43例患者接受通络祛痛膏结合医用橡皮膏胶带“马镫”式固定治疗(通络膏联合胶带组)。采用视觉模拟评分表(VAS)、踝关节肿胀程度、美国足踝骨科协会踝-后足评分(AOFAS-AHS)、踝关节Karlsson-Peterson评分系统评估临床疗效。结果通络膏、通络膏联合胶带组治疗3 d及治疗1、4、8周后活动性疼痛(POM)VAS评分、肿胀程度、AOFAS-AHS与治疗前比较,差异有统计学意义(P<0.05);通络膏联合胶带组治疗1、8周后POM VAS评分、肿胀程度、AOFAS-AHS及1 a后随访Karlsson-Peterson评分与通络膏组比较,差异有统计学意义(P<0.05)。结论通络祛痛膏结合医用橡皮膏胶带“马镫”式固定可以迅速改善急性LAS患者早期疼痛和肿胀,提高踝关节功能评分,预防踝关节慢性不稳定及残留痛。

基于络病理论探讨通络祛痛法在子宫内膜异位症疼痛中的应用

子宫内膜异位症是妇科疑难疾病,其典型症状为疼痛,且疼痛往往影响患者的身心健康与生活质量。近年来,诸多医家将络病理论应用于临床疼痛类疾病的治疗中,且疗效显著。本文基于络病理论,结合临床经验,总结出子宫内膜异位症疼痛的根本病机为血瘀络阻,不通则痛;临床运用通络祛痛法辨证施治,并附一则验案加以阐述。

通络祛痛膏联合中医推拿手法治疗颈椎病的效果观察

目的:探讨通络祛痛膏联合中医推拿手法治疗颈椎病的效果。方法:选取2019年7月—2021年3月天津市河西区陈塘庄街社区卫生服务中心收治的96例颈椎病患者作为研究对象,随机分为对照组与观察组,各48例。对照组采用中医推拿手法治疗,观察组在对照组基础上给予通络祛痛膏贴敷治疗。比较两组治疗前后中医证候积分、颈椎功能、肩关节功能及临床疗效。结果:治疗后,观察组关节红肿热痛、活动不利、发热烦闷、口渴便黄、舌质红或暗、脉滑数积分均低于对照组,差异有统计学意义(P<0.05)。治疗后,观察组颈椎、肩关节功能评分均高于对照组,差异有统计学意义(P<0.001)。观察组治疗总有效率高于对照组,差异有统计学意义(P=0.021)。结论:通络祛痛膏联合中医推拿手法治疗颈椎病的效果显著,可改善患者临床症状,提高颈椎及肩关节功能。

温经祛痛汤联合脐灸治疗寒凝血瘀型原发性痛经的临床疗效

目的:原发性痛经是一种临床常见妇科疾病,以经期或行经前后小腹疼痛、坠胀,伴腰酸或其他不适,甚至剧痛难以忍受,影响生活为主要表现,临床发病率逐渐增加,且病情反复,对患者的学习、工作及生活造成严重困扰。西医治疗本病以药物止痛治疗为主,能有效缓解疼痛,但不良反应较多,停药易反复,需要长期用药。本研究主要观察自拟温经祛痛汤联合脐灸治疗寒凝血瘀型原发性痛经患者的临床疗效。方法:将寒凝气滞血瘀型的原发性痛经患者(共80例)随机分为治疗组及对照组,每组40例;对照组给予西药布洛芬缓释胶囊,治疗组给予自拟温经祛痛汤联合脐灸治疗,连续治疗3个月经周期,观察对比两组试验对象治疗后的临床疗效。结果:两组治疗后血清前列腺素F2α、缩宫素水平较治疗前明显减少,差异具有统计学意义(P<0.05);前列腺素E2、β-内啡肽水平明显上升,差异具有统计学意义(P<0.05),且治疗组改善更显著,差异具有统计学意义(P<0.05);治疗组总有效率为92.5%(37/40),对照组为75.0%(30/40),组间比较,差异有统计学意义(P<0.05);随访6个月,治疗组疗效稳定,不易复发。结论:自拟温经祛痛汤联合脐灸治疗寒凝血瘀型原发性痛经能有效缓解患者腹痛及临床症状,改善前列腺素、缩宫素、β-内啡肽水平,调节内分泌系统,改善子宫血流量,疗效稳定且不容易复发,值得临床推广。

通络祛痛膏外敷配合牵引治疗神经根型颈椎病的临床观察

目的:分析通络祛痛膏外敷配合牵引治疗神经根型颈椎病的临床效果。方法:选取2019年1月—2021年12月烟台市蓬莱区北沟卫生院收治的神经根型颈椎病患者100例为观察对象,按照随机数字表法分为观察组和对照组,各50例。对照组给予牵引治疗,观察组在对照组基础上给予通络祛痛膏外敷治疗。比较两组患者疼痛强度[视觉模拟疼痛量表(VAS评分)]、中医证候疗效、不良反应发生情况。结果:治疗后,观察组患者VAS评分低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。观察组治疗总有效率高于对照组,差异有统计学意义(P<0.001)。两组均未出现治疗相关的不良反应。结论:在牵引治疗基础上配合通络祛痛膏外敷治疗神经根型颈椎病操作便捷,疗效显著,可改善患者疼痛情况,安全性高。

通络祛痛膏治疗纤维肌痛综合征效果观察

目的:观察通络祛痛膏治疗纤维肌痛综合征(FS)的效果。方法:选取2021年1月—2022年12月北京市怀柔区九渡河镇社区卫生服务中心收治的60例FS患者,采用随机数字表法分成对照组和观察组各30例。对照组给予常规治疗,观察组在对照组基础上采取通络祛痛膏治疗,比较两组的治疗效果,治疗前后的改良纤维肌痛影响调查表(FIQR)、匹兹堡睡眠质量指数量表(PSQI)、视觉模拟量表(VAS)得分及压痛点数,并统计两组副反应发生率。结果:观察组治疗总有效率(96.67%)高于对照组(76.67%),差异有统计学意义(P<0.05)。治疗前,两组FIQR、PSQI、VAS得分及压痛点数比较,差异无统计学意义(P>0.05);治疗后,两组FIQR、PSQI、VAS得分均低于治疗前、压痛点数少于治疗前,差异有统计学意义(P<0.05),且观察组FIQR、PSQI、VAS得分低于对照组、压痛点数少于对照组,差异有统计学意义(P<0.05)。两组头晕及嗜睡等副反应发生率比较,差异无统计学意义(P>0.05)。结论:通络祛痛膏治疗FS效果理想,能减轻患者疼痛感,改善患者临床症状和睡眠质量,且安全性较高,值得临床应用。

去痛片（索密痛）的胶束动电毛细管色谱测定

本文应用胶束动电毛细管色谱法分析去痛片（索密痛）。选择十二烷基硫酸钠为胶束相，运行液为０．０２ｍｏｌ／Ｌ磷酸盐缓冲液（ｐＨ＝１０．０），恒定电压１６ｋＶ（电流１０５～１１５μＡ），可使样品中４个组分完全分离，保留时间分别在６～１１ｍｉｎ内，ＲＳＤ均小于０．５％（ｎ＝１０）．各组分溶液在２５～５００μｇ／ｍｌ范围内浓度与峰面积之间有良好的线性关系。选用乙酰苯胺为内标物，测定样品含量。批内各组分测定值的ＲＳＤ均小于１％（ｎ＝９）。

强腰祛痛汤联合西药治疗腰椎间盘突出症经皮椎间孔镜髓核摘除术后残留神经症状疗效观察

目的研究腰椎间盘突出症患者经皮椎间孔镜髓核摘除术后采用强腰祛痛汤联合甲钴胺、塞来昔布治疗的临床效果及对患者残留神经症状的影响。方法将84例经皮椎间孔镜髓核摘除术治疗后残留神经症状的腰椎间盘突出症患者按随机数字表法分为两组各42例。对照组、观察组分别采用甲钴胺+塞来昔布以及甲钴胺+塞来昔布+强腰祛痛汤治疗。观察两组患者治疗效果、腰椎功能、疼痛状况、生活质量以及不良反应情况。结果观察组治疗总有效率(92.86%)高于对照组(83.33%),差异有统计学意义(P<0.05)。治疗后两组腰椎功能均较治疗前有改善(P<0.05),且观察组改善优于对照组(P<0.05)。治疗后两组视觉模拟疼痛评分(visual analogue score,VAS)、日常生活量表(activity of dailyLiving scale,ADL)评分均较治疗前改善(P<0.05),且观察组上述评分均优于对照组(P<0.05)。观察组不良反应发生率(19.05%)与对照组(14.29%)比较差异无统计学意义(P>0.05)。结论强腰祛痛汤联合甲钴胺和塞来昔布对腰椎间盘突出症经皮椎间孔镜髓核摘除术后残留神经症状的患者具有较好疗效,能明显改善患者残留神经症状,缓解患者疼痛,提高患者生活质量,安全性较高,值得临床应用及推广。

GC法同时测定通络祛痛膏中丁香酚等挥发性组分

目的建立气相色谱法同时测定通络祛痛膏中樟脑、薄荷脑、冰片和丁香酚等4种成分含量的方法。方法以萘为内标物,挥发油测定法制备供试液。HP-INNOWAX毛细管色谱柱,氮气为载气,FID检测器,程序升温,测定样品中4种成分的含量。结果通络祛痛膏中樟脑、薄荷脑、冰片(龙脑和异龙脑)和丁香酚及内标物萘等5种物质在同一色谱条件下获得良好分离,平均回收率(n=6)分别为99.89%(RSD=1.16%),96.76%(RSD=0.76%)、97.53%(RSD=0.95%)和99.38%(RSD=1.58%)。采用此法对12批样品进行含量测定,均取得了满意的结果。结论该方法简便、准确,分离度好,可用于通络祛痛膏的质量控制。

胶束动电毛细管色谱法分离测定去痛片中的4种组分

目的 建立一种用胶束动电毛细管色谱法测定去痛片中各组分含量的方法。方法 用硼酸·氢氧化钠·十二烷基磺酸钠为缓冲液进行分离。以茶碱为内标，２５４ｎｍ为测定波长结果 样品中咖啡因、氨基比林、非那西丁、苯巴比妥等４组分完全分离且呈良好线性关系，其加样回收率为９８．２６％￣１０１．８７％。结论 本方法简便、准确、可作为该制剂各组分含量的测定方法。